Hepatitis vaccines

Medical Clinics of North America

Volumn 80, Issue 5, 1996, Pages 1189-1200

  Katkov, W N ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS VACCINE; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INTERFERON; INTERLEUKIN 2; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; NONHUMAN; PASSIVE IMMUNIZATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROCONVERSION; VACCINATION; VIRUS HEPATITIS;

EID: 0029739046     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70485-5     Document Type: Article

References (89)

1. P.C. Alexander R. Johnson W.W. Williams Hepatitis B vaccination programs for health care personnel in US hospitals Public Health Rep 105 1990 610 616
2. C.A. Alper M.S. Kruskall D. Marcus-Bagley Genetic prediction of nonresponse to hepatitis B vaccine N Engl J Med 321 1989 708 712
3. H.J. Alter B.W. Jett A.J. Polito Analysis of the role of hepatitis C virus in transfusion-associated hepatitis F.B. Hollinger S.M. Lemon H. Margolis Viral Hepatitis and Liver Disease 1991 Williams & Wilkins Baltimore 396 402
4. H.J. Alter R.H. Purcell J.W. Shih Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B N Engl J Med 321 1989 1494 1500
5. M.J. Alter P.J. Coleman W.J. Alexander Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis JAMA 262 1989 1201 1205
6. M.J. Alter S.C. Hadler F.N. Judson Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection JAMA 264 1990 2231 2235
7. H. Briem A. Safary Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later J Med Virol 44 1994 443 445
8. J. Bukh R.H. Purcll R.H. Miller At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide Proc Natl Acad Sci 90 1993 8234
9. Centers for Disease Control Protection against viral hepatitis: Non-A, non-B hepatitis MMWR 39 RR-2 1990 23
10. Q.-L. Choo G. Kuo R. Ralston Vaccination of chimpanzees against infection by the hepatitis C virus Proc Natl Acad Sci USA 91 1994 1294 1298
11. Q.-L. Choo G. Kuo A.J. Weiner Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
12. R. Clemens A. Safary A. Hepburn Clinical experience with an inactivated hepatitis A vaccine J Infect Dis 171 suppl 1 1995 S44 S49
13. A.C. Collier L. Corey V.L. Murphy Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination Ann Intern Med 109 1988 101 105
14. M.E. Conrad S.M. Lemon Prevention of icteric viral hepatitis by administration of immune serum gamma globulin J Infect Dis 156 1987 56 63
15. Committee on Epidemic Diseases Acute viral hepatitis surveillance, 1990 Epidemiol News Bull Singapore 17 1991 37 39
16. Committee on Infectious Diseases, American Academy of Pediatrics Universal hepatitis B immunization Pediatrics 89 1992 795 800
17. P. Coursaget B. Yvonnet P. Anthonioz Immunogenicity of a hepatitis B vaccine obtained by genetic recombination and containing products of S and pre-S2 genes Presse Med 17 1988 1550 1551
18. D.E. Craven Z.L. Awdeh L.M. Kunches Nonresponsiveness to hepatitis B vaccine in health care workers: Results of revaccination and genetic typings Ann Intern Med 105 1986 356 360
19. A. Delem A. Safary F. De Namur Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A Vaccine 11 1993 479 484
20. J.L. Dienstag B.G. Werner M.F. McLane Absence of antibodies to HTLV-III in health workers after hepatitis B vaccination JAMA 254 1985 1064 1066
21. E.F. Ellerbeck J.A. Lewis D. Nalin Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A Vaccine 10 suppl 1 1992 s
22. P. Farci H.J. Alter S. Govindarajan Lack of protective immunity against reinfection with hepatitis C virus Science 258 1992 135 140
23. A.L. Franks C.J. Berg M.A. Kane Hepatitis B virus infection among children born in the United States to Southeast Asian refugees N Engl J Med 321 1989 1301 1305
24. P. Gardner T. Eickhoff G.A. Poland Adult immunizations Ann Intern Med 12 1 pt 1 1996 35 40
25. A. Gibas E. Watkins J.L. Dienstag Long-term persistence of protective antibody after hepatitis B vaccination of healthy adults A.J. Zuckerman Viral Hepatitis and Liver Disease 1988 Alan R. Liss New York 998 1001
26. P.J. Grob H.I. Joller-Jemelka U. Binswanger Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations Eur J Clin Microbiol 3 1984 195 198
27. I.E. Gust N.I. Lehmann S. Crowe The origin of the HM175 strain of hepatitis A virus J Infect Dis 151 1985 365 367
28. S.C. Hadler Global impact of hepatitis A infection changing patterns F.B. Hollinger S.M. Lemon H.S. Margolis Viral Hepatitis and Liver Disease 1991 Williams & Wilkins Baltimore 14 20
29. S.C. Hadler D.P. Francis J.E. Maynard Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men N Engl J Med 315 1986 209 214
30. S.C. Hadler H.M. Webster J.J. Erben Hepatitis A in day-care centers: A community-wide assessment N Engl J Med 302 1980 1222 1227
31. Hepatitis surveillance: Report no. 52. Atlanta, Centers for Disease Control, Public Health Service, 1989
32. P.L. Hibberd R.H. Rubin Immunization strategies for the immunocompromised host: The need for immunoadjuvants Ann Intern Med 110 1989 955 956
33. J.H. Hoofnagle Toward universal vaccination against hepatitis B virus N Engl J Med 321 1989 1333 1334
34. M. Houghton A. Weiner J. Han Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease Hepatology 14 1991 381 388
35. S. Iino S. Fujiyama K. Horiuchi Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers Vaccine 10 1992 323 328
36. Immunization Practices Advisory Committee Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination MMWR 40 RR-13 1991 1 25
37. I.M. Jacobson G. Jaffers J.L. Dienstag Immunogenicity of hepatitis B vaccine in renal transplant recipients Transplantation 39 1985 393 395
38. B. Kallinowski K. Gmelin B. Kommerell Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine: A randomized multicentre study with three consecutive vaccine lots Vaccine 10 1992 500 501
39. J.-H. Kao P.-J. Chen M.-Y. Lai Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis Gastroenterology 105 1993 583 587
40. W.N. Katkov E. Watkins H.C. DeMlia Immunogenicity of a “pre-S2 plus S” hepatitis B vaccine in healthy adults J Viral Hepatitis 1 1994 79
41. R.G. Knodell M.E. Conrad A.L. Ginsburg Efficacy of prophylactic gammaglobulin in preventing non-A, non-B post-transfusion hepatitis Lancet 1 1976 557 561
42. R.S. Koff Seroepidemiology of hepatitis A in the United States J Infect Dis 171 suppl 1 1995 S19 S23
43. S. Krugman M. Davidson Hepatitis B vaccine: Prospects for duration of immunity Yale J Biol Med 60 1987 333 338
44. S. Krugman J.P. Giles J. Hammond Hepatitis virus: Effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains J Infect Dis 122 1970 432 436
45. G. Kuo Q.-L. Choo H.J. Alter An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis Science 244 1989 362 364
46. Y.Y. Kusov L.B. Elbert I.V. Nelga Immunogenicity trial of inactivated hepatitis A virus vaccine in human volunteers Vaccine 9 1991 540 541
47. C.-L. Lai Wong B.C.-Y. E.-K. Yeoh Five year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses Hepatology 18 1993 763 767
48. J.A. Lewis M.E. Armstrong V.M. Larson Use of a live attenuated hepatitis A vaccine to prepare a highly purified formalin-inactivated hepatitis A vaccine F.B. Hollinger S.M. Lemon H.S. Margolis Viral Hepatitis and Liver Disease 1991 Williams & Wilkins Baltimore 736 741
49. H.S. Margolis Prevention of acute and chronic liver disease through immunization: Hepatitis B and beyond J Infect Dis 168 1993 9 14
50. H.S. Margolis Who should receive hepatitis A vaccine? Considerations for the development of an immunization strategy Vaccine 10 suppl 1 1992 s85 s86
51. B.J. McMahon M. Beller J. Williams A program to control an outbreak of hepatitis A in Alaska using an inactivated hepatitis A vaccine [abstrt] Program and Abstracts 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994 American Society for Microbiology Washington, DC
52. J.L. Melnick History and epidemiology of hepatitis A virus J Infect Dis 171 suppl 1 1995 S2 S8
53. S.C. Meuer H. Dumann K.H. Meyer zum Buschenfelde Low dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination Lancet 1 1989 15 17
54. D.R. Milich F.V. Chisari Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg): I. H-2 restriction of the murine humoral response to the a and d determinants of HBsAg J Immunol 129 1982 320 325
55. D.R. Milich G.G. Leroux-Roels F.V. Chisari Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg): II. Qualitative characteristics of the humoral immune response to the a, d, and y determinants of HBsAg J Immunol 130 1983 1395 1400
56. D.R. Milich M.K. McNamara A. McLachlan Distinct H2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of non-responsiveness to the S region Proc Natl Acad Sci USA 82 1985 8168 8172
57. D.R. Milich G.B. Thornton A.R. Neurath Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen Science 228 1985 1195 1199
58. J. Miskovsky K. Gershman M. Clements Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2+S antigens Vaccine 9 1991 346 350
59. V. Pellegrini N. Fineschi G. Matteucci Preparation and immunogenicity of an inactivated hepatitis A vaccine Vaccine 11 1993 383 387
60. Prevention of perinatal transmission of hepatitis B virus: Prenatal screening of all pregnant women for hepatitis B surface antigen MMWR 37 1988 341 351
61. V. Prikazsky V. Olear A. Cernoch Interruption of an outbreak of hepatitis A in two villages by vaccination J Med Virol 44 1994 457 459
62. P.J. Provost M.R. Hilleman An inactivated hepatitis A virus vaccine prepared from infected marmoset liver Proc Soc Exp Biol Med 159 1978 201 203
63. O.W. Prozesky C.E. Stevens W. Szmuness Immune response of hepatitis B vaccine in newborns J Infect 7 suppl 1 1983 53 55
64. Recommended Childhood Immunization Schedule, United States—January to June 1996 (Special Medical Reports) Am Fam Phys 53 1996 392 396
65. A.J. Roome S.J. Walsh M.L. Cartter Hepatitis B vaccine responsiveness in Connecticut public safety pronnel JAMA 270 1993 2931 2934
66. A. Sanchez-Quijano J.A. Pineda E. Lissen Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients Lancet 1 1988 1245 1249
67. E.M. Scolnick A.A. McLean D.J. West Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA JAMA 251 1984 2812 2815
68. L.B. Seeff J.H. Zimmerman E.C. Wright A randomized double-blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis: A Veterans Administration cooperative study Gastroenterology 72 1977 111 121
69. Y.K. Shimizu M. Hijikata A. Iwamoto Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses J Virol 68 1994 1494 1500
70. C.E. Stevens H.J. Alter P.E. Taylor Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy N Engl J Med 311 1984 496 501
71. C.E. Stevens R.P. Beasley J. Tsui Vertical transmission of hepatitis B antigen in Taiwan N Engl J Med 292 1975 771 774
72. C.E. Stevens F.E. Taylor M.J. Tong Hepatitis B vaccine: An overview G.N. Vyas J.L. Dienstag J.H. Hoofnagle Viral Hepatitis and Liver Disease 1984 Grune & Stratton Orlando 275 291
73. C.E. Stevens P.E. Taylor J. Pindyck Epidemiology of hepatitis C virus: A preliminary study in volunteer blood donors JAMA 263 1990 49 53
74. C.E. Stevens P.T. Toy F.E. Taylor Prospects for control of hepatitis B virus infection: Implications of childhood vaccination and long-term protection Pediatrics 90 1992 170 173
75. C.E. Stevens P.T. Toy M.J. Tong Perinatal hepatitis B virus transmission in the United States: Prevention by passive-active immunization JAMA 253 1985 1740 1745
76. W. Szmuness C.E. Stevens E.J. Harley Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States N Engl J Med 303 1980 833 841
77. K.L. Tan K.T. Goh C.J. Oon Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization JAMA 271 1994 859 861
78. N.C. Tassopoulos G.J. Papaevangelou M.H. Sjogren Natural history of acute hepatitis B surface antigen-positive hepatitis in greek adults Gastroenterology 92 1987 1844 1850
79. F. Tron F. Degos C. Brechot Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences J Infect Dis 160 1989 199 204
80. T. Ukena H. Esber R. Bessette Site of injection and response to hepatitis B vaccine N Engl J Med 313 1985 579 580
81. J.B. Ulmer J.J. Donnelly S.E. Parker Heterologous protection against influenza by injection of DNA encoding viral protein Science 259 1993 1745 1749
82. Update on hepatitis B prevention MMWR 36 1989 353 360
83. P. Van Damme S. Thoelen M. Cramm Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence J Med Virol 44 1994 446 451
84. M.E. Walker W. Szmuness C.E. Stevens Genetics of anti-HBS responsiveness: I. HLA-DR7 and non-responsiveness to hepatitis vaccination [abstrt] Transfusion 21 1981 601
85. H. Watanabe S. Matsushita N. Kanikawaji Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ supressor T cells Hum Immunol 22 1988 9 17
86. A.J. Weiner H.M. Geysen C. Christopherson Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoproteinvariants: Potential role in chronic HCV infections Proc Natl Acad Sci 89 1992 3468 3472
87. A.B. Weitberg S.A. Weitzman E. Watkins Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy J Clin Oncol 3 1985 718 722
88. A. Werzberger B. Mensch B. Kuter A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children N Engl J Med 327 1992 453 457
89. R.C. Wood K.L. MacDonald K.E. White Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers JAMA 270 1993 2935 2939